A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
Conditions
Cystic Fibrosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The University of Alabama at Birmingham, Birmingham, Alabama, United States
University of Arizona, Tucson, Arizona, United States
Stanford University, Palo Alto, California, United States
UCSD, San Diego, California, United States
National Jewish Health, Denver, Colorado, United States
Emory University, Atlanta, Georgia, United States
Boston Children's Hospital, Boston, Massachusetts, United States
New York Medical College, Valhalla, New York, United States
The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Oregon Health & Science University, Portland, Oregon, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
UT Southwestern Medical Center, Dallas, Texas, United States
University of Washington, Seattle, Washington, United States
Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier, France
Hôpital Necker Enfants Malades, Paris, France
UMC Utrecht, Utrecht, Netherlands
New Zealand Clinical Research (Part 1 Only), Auckland, New Zealand
University Hospitals Birmingham, Birmingham, United Kingdom
Royal Papworth Hospital, Cambridge, United Kingdom
Leeds Teaching Hospitals, Leeds, United Kingdom
King's College Hospital, London, United Kingdom
Nottingham University Hospitals, Nottingham, United Kingdom
University Hospital Southampton, Southampton, United Kingdom
Study leads
John Matthews, MBBS, MCRP, PhD
Study Chair
ReCode Therapeutics, Inc.